Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Código da empresaCPRX
Nome da EmpresaCatalyst Pharmaceuticals Inc
Data de listagemNov 08, 2006
CEODaly (Richard J)
Número de funcionários181
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 08
Endereço355 Alhambra Circle
CidadeCORAL GABLES
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33134
Telefone13055292522
Sitehttps://catalystpharma.com/
Código da empresaCPRX
Data de listagemNov 08, 2006
CEODaly (Richard J)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados